JP2020525436A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020525436A5 JP2020525436A5 JP2019570906A JP2019570906A JP2020525436A5 JP 2020525436 A5 JP2020525436 A5 JP 2020525436A5 JP 2019570906 A JP2019570906 A JP 2019570906A JP 2019570906 A JP2019570906 A JP 2019570906A JP 2020525436 A5 JP2020525436 A5 JP 2020525436A5
- Authority
- JP
- Japan
- Prior art keywords
- controlled release
- compound
- dosage form
- gastric resistance
- resistance controlled
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000013270 controlled release Methods 0.000 claims 33
- 230000002496 gastric effect Effects 0.000 claims 26
- 150000001875 compounds Chemical class 0.000 claims 22
- 239000002552 dosage form Substances 0.000 claims 22
- 150000003839 salts Chemical class 0.000 claims 10
- 239000012453 solvate Substances 0.000 claims 10
- 239000003795 chemical substances by application Substances 0.000 claims 8
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims 5
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims 5
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims 5
- 229960003943 hypromellose Drugs 0.000 claims 5
- 239000000314 lubricant Substances 0.000 claims 4
- 238000003745 diagnosis Methods 0.000 claims 2
- 239000002702 enteric coating Substances 0.000 claims 2
- 238000009505 enteric coating Methods 0.000 claims 2
- 239000000945 filler Substances 0.000 claims 2
- 239000002207 metabolite Substances 0.000 claims 2
- 201000000980 schizophrenia Diseases 0.000 claims 2
- 108010001237 Cytochrome P-450 CYP2D6 Proteins 0.000 claims 1
- 102100021704 Cytochrome P450 2D6 Human genes 0.000 claims 1
- 239000000853 adhesive Substances 0.000 claims 1
- 230000000181 anti-adherent effect Effects 0.000 claims 1
- 238000004090 dissolution Methods 0.000 claims 1
- -1 hydroxypropoxy Chemical group 0.000 claims 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 229920000642 polymer Polymers 0.000 claims 1
- 238000013268 sustained release Methods 0.000 claims 1
- 239000012730 sustained-release form Substances 0.000 claims 1
- 208000024891 symptom Diseases 0.000 claims 1
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023147484A JP2023175778A (ja) | 2017-06-21 | 2023-09-12 | 胃耐性制御放出経口剤形 |
| JP2025101290A JP2025134828A (ja) | 2017-06-21 | 2025-06-17 | 胃耐性制御放出経口剤形 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762523204P | 2017-06-21 | 2017-06-21 | |
| US62/523,204 | 2017-06-21 | ||
| PCT/US2018/038853 WO2018237207A1 (en) | 2017-06-21 | 2018-06-21 | Gastro-resistant controlled release oral dosage forms |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023147484A Division JP2023175778A (ja) | 2017-06-21 | 2023-09-12 | 胃耐性制御放出経口剤形 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2020525436A JP2020525436A (ja) | 2020-08-27 |
| JP2020525436A5 true JP2020525436A5 (OSRAM) | 2021-07-29 |
Family
ID=62904624
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019570906A Pending JP2020525436A (ja) | 2017-06-21 | 2018-06-21 | 胃耐性制御放出経口剤形 |
| JP2023147484A Pending JP2023175778A (ja) | 2017-06-21 | 2023-09-12 | 胃耐性制御放出経口剤形 |
| JP2025101290A Pending JP2025134828A (ja) | 2017-06-21 | 2025-06-17 | 胃耐性制御放出経口剤形 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023147484A Pending JP2023175778A (ja) | 2017-06-21 | 2023-09-12 | 胃耐性制御放出経口剤形 |
| JP2025101290A Pending JP2025134828A (ja) | 2017-06-21 | 2025-06-17 | 胃耐性制御放出経口剤形 |
Country Status (15)
| Country | Link |
|---|---|
| US (3) | US11464744B2 (OSRAM) |
| EP (1) | EP3641732A1 (OSRAM) |
| JP (3) | JP2020525436A (OSRAM) |
| CN (1) | CN111511353A (OSRAM) |
| AU (2) | AU2018290287B2 (OSRAM) |
| BR (1) | BR112019027398A2 (OSRAM) |
| CA (1) | CA3067031A1 (OSRAM) |
| CL (1) | CL2019003743A1 (OSRAM) |
| CO (1) | CO2019014496A2 (OSRAM) |
| IL (3) | IL319156A (OSRAM) |
| MX (1) | MX2023002994A (OSRAM) |
| PE (1) | PE20200732A1 (OSRAM) |
| UA (1) | UA127349C2 (OSRAM) |
| WO (1) | WO2018237207A1 (OSRAM) |
| ZA (1) | ZA202409847B (OSRAM) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2968977A1 (en) | 2014-12-02 | 2016-06-09 | Minerva Neurosciences, Inc. | Compositions comprising 2-((1-(2(4-fluorophenyl)-2-oxoethyl)piperidin-4-yl)methyl)isoindolin-1-one for treating schizophrenia |
| EP3641732A1 (en) | 2017-06-21 | 2020-04-29 | Minerva Neurosciences, Inc. | Gastro-resistant controlled release oral dosage forms |
| WO2020041504A1 (en) | 2018-08-21 | 2020-02-27 | Minerva Neurosciences, Inc. | Use of roluperidone to treat negative symptoms and disorders, increase neuroplasticity, and promote neuroprotection |
| IT201800011125A1 (it) * | 2018-12-14 | 2020-06-14 | Dpl Pharma S P A | Composizioni farmaceutiche orali solide comprendenti matrici monolitiche complesse per la somministrazione cronotropica di medicamenti nel tratto gastroenterico |
| CA3243767A1 (en) | 2022-02-14 | 2023-08-17 | Minerva Neurosciences, Inc. | USE OF ROLUPERIDONE IN THE PREVENTION OF RELAPSE IN PATIENTS WITH SCHIZOPHRENIA |
| WO2025090588A1 (en) | 2023-10-24 | 2025-05-01 | Minerva Neurosciences, Inc. | Roluperidone for the treatment of lysosomal storage disorders and their symptoms |
Family Cites Families (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0325063B1 (en) | 1988-01-21 | 1994-03-09 | Merrell Dow Pharmaceuticals Inc. | Use of 1,4-disubstituted-piperidinyl compounds in the manufacture of a medicament for the treatment of insomnia |
| ZA908641B (en) | 1989-10-27 | 1992-06-24 | Du Pont | (n-phthalimidoalkyl)piperidines |
| NZ251610A (en) | 1992-04-23 | 1996-02-27 | Merrell Dow Pharma | 4-imidomethyl-1-(2-phenyl-2-oxoethyl)piperidine derivatives and pharmaceutical compositions |
| PT1260512E (pt) | 2000-02-29 | 2007-10-10 | Mitsubishi Pharma Corp | ''novos derivados de amida cíclicos'' |
| WO2002026214A1 (en) | 2000-09-29 | 2002-04-04 | Solvay Pharmaceuticals B.V. | Ion-strength independent sustained release pharmaceutical formulation |
| US20050095292A1 (en) | 2003-10-29 | 2005-05-05 | Wyeth | Sustained release pharmaceutical compositions |
| MY147202A (en) * | 2003-11-26 | 2012-11-14 | Novartis Ag | Compositions comprising organic compounds |
| TW200616608A (en) | 2004-07-09 | 2006-06-01 | Forest Laboratories | Memantine as adjunctive treatment to atypical antipsychotics in schizophrenia patients |
| DOP2006000125A (es) | 2005-06-06 | 2006-12-31 | Merck Sharp & Dohme | Derivados de ciclohexanosulfonilo como inhibidores de glyt1 para tratar esquizofrenia |
| JP2009525979A (ja) | 2006-02-07 | 2009-07-16 | 田辺三菱製薬株式会社 | ４−アシルアミノピリジン誘導体を介した神経新生 |
| CA2569776A1 (en) | 2006-02-17 | 2007-08-17 | Kos Life Sciences, Inc. | Low flush niacin formulation |
| TW200817400A (en) | 2006-05-30 | 2008-04-16 | Elbion Ag | Pyrido [3,2-e] pyrazines, their use as inhibitors of phosphodiesterase 10, and processes for preparing them |
| JP2008273954A (ja) | 2007-03-30 | 2008-11-13 | Mitsubishi Tanabe Pharma Corp | うつ病の予防及び／又は治療剤 |
| GB2462611A (en) | 2008-08-12 | 2010-02-17 | Cambridge Lab | Pharmaceutical composition comprising tetrabenazine |
| EP2246331A1 (en) | 2009-04-24 | 2010-11-03 | Westfälische Wilhelms-Universität Münster | NR2B-selective NMDA-receptor antagonists |
| JP5640079B2 (ja) * | 2009-05-18 | 2014-12-10 | シグモイド・ファーマ・リミテッドＳｉｇｍｏｉｄ Ｐｈａｒｍａ Ｌｉｍｉｔｅｄ | 油滴含有組成物 |
| UY33455A (es) | 2010-06-16 | 2012-01-31 | Teijin Pharma Ltd | Tableta con núcleo recubierto de liberación controlada |
| US8937900B2 (en) | 2010-07-20 | 2015-01-20 | Qualcomm Incorporated | Enhancing pilot channel transmission in TD-SCDMA multicarrier systems using secondary carrier frequencies |
| EP3335731B1 (en) | 2010-07-20 | 2024-09-04 | Minerva Neurosciences, Inc. | Use of cyclic amide derivatives to treat sleep disorders |
| EP4070794A3 (en) | 2010-07-20 | 2023-01-18 | Minerva Neurosciences, Inc. | Methods of use cyclic amide derivatives to treat sigma receptor-mediated disorders |
| US20120040008A1 (en) | 2010-08-11 | 2012-02-16 | Ashish Chatterji | Pharmaceutical compositions of metabotropic glutamate 5 receptor (mglu5) antagonists |
| EP2468264A1 (en) * | 2010-12-27 | 2012-06-27 | Laboratorios Liconsa, S.A. | Oral pharmaceutical tablet for controled release of mesalazine and process for obtaining it |
| US9737531B2 (en) | 2012-07-12 | 2017-08-22 | Glytech, Llc | Composition and method for treatment of depression and psychosis in humans |
| EP2685966A1 (en) | 2011-03-17 | 2014-01-22 | Lupin Limited | Controlled release pharmaceutical compositions of selective serotonin reuptake inhibitor |
| CA2845228C (en) * | 2011-08-16 | 2021-08-10 | Baker Idi Heart & Diabetes Institute Holdings Limited | Oral controlled-release formulation of 5-(pyridinyl)-2(1h)-pyridinone compounds |
| BR112015023124A2 (pt) * | 2013-03-14 | 2017-07-18 | Therabiome Llc | liberação de organismos probióticos e/ou agentes terapêuticos almejada para o trato gastrintestinal |
| CN104586771B (zh) * | 2013-10-30 | 2018-01-16 | 广州朗圣药业有限公司 | 一种盐酸坦洛新缓释微丸制剂 |
| MX2016014192A (es) | 2014-04-30 | 2017-05-01 | Incyte Corp | Procesos para preparar un inhibidor de cinasas de janus 1 (jak1) y nuevas formas de este. |
| EP3144308B1 (en) | 2014-05-16 | 2020-06-24 | Takeda Pharmaceutical Company Limited | Nitrogen-containing heterocyclic compound |
| WO2015191554A1 (en) | 2014-06-09 | 2015-12-17 | Intra-Cellular Therapies, Inc. | Compounds and methods of use to treat schizophrenia |
| RU2697851C2 (ru) * | 2014-08-13 | 2019-08-21 | Седарс-Синаи Медикал Сентер | Антиметаногенные композиции и их применение |
| CA2968977A1 (en) | 2014-12-02 | 2016-06-09 | Minerva Neurosciences, Inc. | Compositions comprising 2-((1-(2(4-fluorophenyl)-2-oxoethyl)piperidin-4-yl)methyl)isoindolin-1-one for treating schizophrenia |
| WO2017066134A1 (en) * | 2015-10-16 | 2017-04-20 | Merck Sharp & Dohme Corp. | Processes for preparing formulations for gastrointestinal-targeted therapies |
| SG11201810358YA (en) | 2016-05-25 | 2018-12-28 | Mitsubishi Tanabe Pharma Corp | Compositions and methods for treating negative symptoms in non-schizophrenic patients |
| EP3641732A1 (en) | 2017-06-21 | 2020-04-29 | Minerva Neurosciences, Inc. | Gastro-resistant controlled release oral dosage forms |
| WO2020041504A1 (en) | 2018-08-21 | 2020-02-27 | Minerva Neurosciences, Inc. | Use of roluperidone to treat negative symptoms and disorders, increase neuroplasticity, and promote neuroprotection |
| US12441701B2 (en) | 2019-06-28 | 2025-10-14 | Tapi Czech Industries S.R.O. | Solid state forms of roluperidone and salts thereof |
| CA3243767A1 (en) | 2022-02-14 | 2023-08-17 | Minerva Neurosciences, Inc. | USE OF ROLUPERIDONE IN THE PREVENTION OF RELAPSE IN PATIENTS WITH SCHIZOPHRENIA |
-
2018
- 2018-06-21 EP EP18740435.5A patent/EP3641732A1/en active Pending
- 2018-06-21 AU AU2018290287A patent/AU2018290287B2/en active Active
- 2018-06-21 JP JP2019570906A patent/JP2020525436A/ja active Pending
- 2018-06-21 IL IL319156A patent/IL319156A/en unknown
- 2018-06-21 CN CN201880054407.9A patent/CN111511353A/zh active Pending
- 2018-06-21 IL IL271606A patent/IL271606B2/en unknown
- 2018-06-21 BR BR112019027398-0A patent/BR112019027398A2/pt active Search and Examination
- 2018-06-21 IL IL308650A patent/IL308650B2/en unknown
- 2018-06-21 UA UAA202000290A patent/UA127349C2/uk unknown
- 2018-06-21 US US16/015,151 patent/US11464744B2/en active Active
- 2018-06-21 PE PE2019002573A patent/PE20200732A1/es unknown
- 2018-06-21 WO PCT/US2018/038853 patent/WO2018237207A1/en not_active Ceased
- 2018-06-21 CA CA3067031A patent/CA3067031A1/en active Pending
-
2019
- 2019-12-18 CL CL2019003743A patent/CL2019003743A1/es unknown
- 2019-12-18 MX MX2023002994A patent/MX2023002994A/es unknown
- 2019-12-20 CO CONC2019/0014496A patent/CO2019014496A2/es unknown
-
2022
- 2022-06-15 US US17/841,284 patent/US12048768B2/en active Active
-
2023
- 2023-09-12 JP JP2023147484A patent/JP2023175778A/ja active Pending
-
2024
- 2024-06-10 US US18/738,782 patent/US20250009665A1/en active Pending
- 2024-09-13 AU AU2024219717A patent/AU2024219717A1/en active Pending
- 2024-12-19 ZA ZA2024/09847A patent/ZA202409847B/en unknown
-
2025
- 2025-06-17 JP JP2025101290A patent/JP2025134828A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020525436A5 (OSRAM) | ||
| JP6084161B2 (ja) | ７−［４−（４−ベンゾ［ｂ］チオフェン−４−イル−ピペラジン−１−イル）ブトキシ］−１Ｈ−キノリン−２−オン又はその塩を含む錠剤 | |
| FI117961B (fi) | Nopeasti vaikutuksen aloittava formulaatio | |
| JP2015506377A5 (OSRAM) | ||
| JP2009525343A5 (OSRAM) | ||
| CN105142618A (zh) | 提供药理及临床效应的莫沙必利每日单次施用缓释制剂 | |
| JP2016516698A5 (OSRAM) | ||
| JP2014501267A (ja) | メサラジン制御放出用の経口用医薬錠剤および前記錠剤を得るための製法 | |
| JP2015510916A5 (OSRAM) | ||
| JP2013529665A5 (OSRAM) | ||
| WO2014029953A1 (en) | Hot melt extruded (hme) pharmaceutical composition of cinacalcet | |
| AU2014279743B2 (en) | Modified release formulation | |
| WO2013084089A1 (en) | Methods for treating cardiovascular disorder | |
| JP2015509539A5 (OSRAM) | ||
| CN101431992A (zh) | 包含尼美舒利的新型低剂量药物组合物及其制备和用途 | |
| JP2010538062A5 (OSRAM) | ||
| JP2016530238A5 (OSRAM) | ||
| CN110035751A (zh) | 一种维利帕尼缓控释药物组合物及其用途 | |
| WO2018095996A1 (en) | Delayed release dosage forms comprising dimethyl fumarate | |
| JP2015120758A5 (OSRAM) | ||
| WO2022138717A1 (ja) | 経口固形製剤 | |
| JP6854162B2 (ja) | 錠剤 | |
| JP6815109B2 (ja) | デュロキセチンまたは薬学的に許容されるその塩を有効成分とする医薬組成物 | |
| CA2854612C (en) | Delivery systems for improving oral bioavailability of fenobam, its hydrates, and salts | |
| EP3439638A1 (en) | Pharmaceutical composition comprising an atypical antipsychotic agent and method for the preparation thereof |